All In Biotech

Drug Trial Radar · NCT06034002

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

290

Planned (sponsor's estimate)

Start

Dec 4, 2023

Primary completion

Oct 29, 2028

Study completion Oct 29, 2028

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Sep 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.

Conditions

  • Myeloproliferative Neoplasms

Interventions

  • INCA033989Drug

    INCA033989 will be administered at protocol defined dose.

  • RuxolitinibDrug

    Rux will be administered according to Prescribing Information/SmPC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
  2. Number of participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 3 years and 60 days

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California · Recruiting

  • Stanford Cancer Institute

    Palo Alto, California · Recruiting

  • University of Miami Health System

    Miami, Florida · Recruiting

  • The University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Icahn School of Medicine At Mount Sinai

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Md Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.